The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Coskun B. N., Dizdar O. S., Korkmaz S., Ulukaya E., EVRENSEL T.

Contemporary oncology (Poznan, Poland), vol.23, no.4, pp.208-213, 2019 (Scopus) identifier identifier identifier


Aim of the study: To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis.